Platin‑based chemotherapy does not improve survival in patients with non‑metastatic resected typical carcinoid tumors

  • Authors:
    • Ahmet Bilgehan Sahin
    • Huseyin Melek
    • Birol Ocak
    • Sibel Oyucu Orhan
    • Buket Erkan
    • Burcu Caner
    • Adem Deligonul
    • Erdem Cubukcu
    • Ahmet Sami Bayram
    • Elif Ulker Akyildiz
    • Turkkan Evrensel
  • View Affiliations

  • Published online on: August 9, 2022     https://doi.org/10.3892/mco.2022.2579
  • Article Number: 146
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemotherapy is controversial in non‑metastatic typical carcinoid (TC) tumors. Therefore, it was aimed to evaluate the impact of platin‑based chemotherapy on the survival of patients with lung TC. The medical records of patients who underwent surgical resection for non‑metastatic TC from 2002 to 2020 at our institution were retrospectively reviewed. Multivariate regression analysis was performed for chemotherapy and prognostic factors in disease‑free survival (DFS) in 72 patients. The pathological stages of patients were as follows: 73.6% of the patients were in stage I, 15.3% in stage II and 11.1% in stage III. A total of 5 patients (6.9%) received platin‑based chemotherapy and 6 patients (8.3%) had recurrences. The DFS rates at 12, 36 and 60 months were 98.5, 95.1 and 92.5%, respectively. Log‑rank testing showed that patients who received chemotherapy and had stage III disease had shorter DFS (P=0.021 for chemotherapy and P<0.001 for stage). However, multivariate analysis revealed that the pathological stage was the only statistically significant factor affecting DFS (P=0.016). Platin‑based chemotherapy did not improve DFS, and the eighth edition of TNM (tumor, nodes, metastases) staging did have prognostic value for patients with non‑metastatic TC. Although resection has satisfying long‑term outcomes, studies on new agents are needed to decrease the recurrence rate, particularly in patients with stage III disease.

Related Articles

Journal Cover

October-2022
Volume 17 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sahin AB, Melek H, Ocak B, Orhan SO, Erkan B, Caner B, Deligonul A, Cubukcu E, Bayram AS, Akyildiz EU, Akyildiz EU, et al: Platin‑based chemotherapy does not improve survival in patients with non‑metastatic resected typical carcinoid tumors. Mol Clin Oncol 17: 146, 2022
APA
Sahin, A.B., Melek, H., Ocak, B., Orhan, S.O., Erkan, B., Caner, B. ... Evrensel, T. (2022). Platin‑based chemotherapy does not improve survival in patients with non‑metastatic resected typical carcinoid tumors. Molecular and Clinical Oncology, 17, 146. https://doi.org/10.3892/mco.2022.2579
MLA
Sahin, A. B., Melek, H., Ocak, B., Orhan, S. O., Erkan, B., Caner, B., Deligonul, A., Cubukcu, E., Bayram, A. S., Akyildiz, E. U., Evrensel, T."Platin‑based chemotherapy does not improve survival in patients with non‑metastatic resected typical carcinoid tumors". Molecular and Clinical Oncology 17.4 (2022): 146.
Chicago
Sahin, A. B., Melek, H., Ocak, B., Orhan, S. O., Erkan, B., Caner, B., Deligonul, A., Cubukcu, E., Bayram, A. S., Akyildiz, E. U., Evrensel, T."Platin‑based chemotherapy does not improve survival in patients with non‑metastatic resected typical carcinoid tumors". Molecular and Clinical Oncology 17, no. 4 (2022): 146. https://doi.org/10.3892/mco.2022.2579